GENE ONLINE|News &
Opinion
Blog

Innovent, Lilly’s PD-1 Inhibitor Approved to Treat Esophageal Cancer in China

by Joy Lin
Share To

Innovent and Eli Lilly have jointly announced the NMPA approval of their TYVYT (sintilimab injection) in combination with chemotherapy for the treatment of esophageal squamous cell carcinoma (ESCC) in the first-line setting. A PD-1 inhibitor, sintilimab will be combined with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy to treat unresectable, locally advanced, recurrent or metastatic cases of ESCC. 

This is sintilimab’s fifth approval in China. Over the last four years, the drug has collected approvals for the treatment of Hodgkin’s lymphoma, non-squamous non-small cell lung cancer (NSCLC), squamous NSCLC, and hepatocellular carcinoma. 

 

Results Based on Orient-15 Study

 

The latest approval of sintilimab is based on the interim analysis of Orient-15, a global Phase 3 clinical trial comparing sintilimab plus chemo to placebo plus chemo in first-line ESCC. 

According to the readout from the Independent Data Monitoring Committee (IDMC), the sintilimab combo showed a statistically significant improvement in overall survival (OS) compared to the placebo combo regardless of PD-L1 expression status, meeting the primary endpoint. 

For sintilimab plus chemo, median OS and median progression-free survival (PFS) were 16.7 months (vs 12.5 months in the placebo group) and 7.2 months (vs 5.7 months for the placebo group).

The safety profile of the sintilimab combo was consistent with that observed in previous studies, with no new safety signals detected. 

Related article: Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange

 

A Competitive PD-1 Inhibitor in China but Not the US

 

Esophageal cancer is the seventh most commonly diagnosed cancer, and the sixth leading cause of cancer death worldwide. It is especially prevalent in China, which makes up more than half of new and fatal global cases. Moreover, the five-year survival rate for the disease is only 30% in the country, highlighting the need for better first-line treatments. 

Having been approved for the first-line setting, sintilimab will have a competitive edge over other PD-1 inhibitors like Merck’s Keytruda (pembrolizumab), which has only been approved for the second-line setting.

Additionally, the NMPA is currently reviewing sintilimab for two indications: in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma, and in combination with bevacizumab biosimilar and chemotherapy for EGFR-mutated non-squamous NSCLC following EGFR-TKI treatment.

While sintilimab has consistently racked up approvals in China, the PD-1 inhibitor does not have as much success in the US where it is still an investigational treatment. In March, the program experienced a setback when the US FDA issued a complete response letter (CRL) to Lilly for the Biologics License Application (BLA) for sintilimab in combination with chemo in first-line non-squamous NSCLC. In the CRL, the FDA requested Lilly and Innovent conduct an additional multiregional clinical study comparing sintilimab with chemo and the standard of care for first-line metastatic NSCLC. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
Eli Lilly and BI Notch Clinical Win for Kidney Disease Drug
2022-11-07
M&A
Eli Lilly Snatches Up Akouos Treating Ear Conditions for $487 million
2022-10-18
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!